Biogen CEO Plots A Slow Return To Growth As Revenue Set To Shrink Again In 2023
Cost Cuts, R&D Prioritization, Deals All On The Table
Christopher Viehbacher told his first earnings call as CEO that a review is under way to reverse Biogen’s fortunes, but noted Leqembi will not be a meaningful contributor while treatment and reimbursement bottlenecks remain.
You may also be interested in...
CEO Chris Viehbacher outlined progress Biogen made in the third quarter, including full approval for the Eisai-partnered Alzheimer’s drug Leqembi, but recent wins will take time to make up for long-term revenue declines.
Eisai recalibrates sales and marketing efforts for Biogen’s multiple sclerosis portfolio in India, joining a growing list of foreign firms that appear to be rightsizing their commercial engine in an ultra-competitive market.
The company is prioritizing investment in the launches of Leqembi, zuranolone and newly approved Qalsody as well as key pipeline assets, while discontinuing investment in two stroke programs.